Research Library / Metabolic / Cagrilintide
Metabolic researchCagrilintide (AM833)
AM833 · Long-acting amylin analog
A long-acting amylin analog being developed for appetite and weight regulation, including in combination with semaglutide. The listed community example (common weekly range) describes 1.2–4.5 mg per administration, once weekly, via subcutaneous; this is not a validated dosing recommendation. An illustrative 5 mg vial at an assumed 2 mL final volume yields 2.5 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 5mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 2.5mg/mL · conditional arithmetic
- One U-100 marking
- 25mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
0.3–4.5 mg · subcutaneous · once weekly · 26 weeks
Adults with overweight or obesityLancet, 2021Reported schedule context
- Range
- 1.2–4.5 mg/week
- Frequency
- Weekly
- Route
- Subcutaneous
- Reported half-life
- ~5 days
- Reported cycle
- Long-term trial schedules; no validated off-cycle
| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Common weekly range | 1.2–4.5 mg | 1.2–4.5 mg/week | Once weekly | Same day each week | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
16.667 example portions per vial
16 full amounts; 0.2 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
0.3 mg · 2.5 mg/mL · 0.12 mL · 12 units
Primary formulation patents investigate buffer, pH, preservative and excipient effects on cagrilintide stability and aggregation. These are formulation-development experiments, not a generic powder-vial label. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
5 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · Common weekly range
Vial counts and final solution totals below use the selected 5 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 1.2–4.5 mg | Once weekly | 1.2–4.5 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 4.8–18 mg | 1–4 × 5 mg |
| 8 weeks | 9.6–36 mg | 2–8 × 5 mg |
| 12 weeks | 14.4–54 mg | 3–11 × 5 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2–8 mL | Not established |
| 8 weeks | 4–16 mL | Not established |
| 12 weeks | 6–22 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 4 |
| 8 weeks | 8 |
| 12 weeks | 12 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 1.11–4.17 administrations
8 weeks: 1.11–4.17 administrations
12 weeks: 1.11–4.17 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Cagrilintide · AM833 · Long-acting amylin analog
- Evidence / status
- Phase III. Investigational — not FDA approved
- Clinical route, frequency & duration
Dose-ranging obesity trial: 0.3–4.5 mg · subcutaneous · once weekly · 26 weeks
- Community purpose
- Appetite suppression, satiety, and weight-management research.
- Reported timing / route
- Weekly · Subcutaneous. Schedule-specific timing remains in the Community tab.
- Reported half-life
- ~5 days · community-reference context, not a shelf life.
- Reported cycle
- Long-term trial schedules; no validated off-cycle. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
Primary formulation patents investigate buffer, pH, preservative and excipient effects on cagrilintide stability and aggregation. These are formulation-development experiments, not a generic powder-vial label.
Other vehicles and approaches discussed
Acidic-buffer and BAC-water methods reported online are not interchangeable. The 5 mg/2 mL card is arithmetic, not proof of a complete preparation or an acid-only rule.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Formulation-dependent aggregation / fibrillation concern
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Formulation-dependent aggregation / fibrillation concern
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Amylin and calcitonin receptor agonist
A long-acting amylin analog being developed for appetite and weight regulation, including in combination with semaglutide.
Community-reported purpose
Appetite suppression, satiety, and weight-management research.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Dose-ranging obesity trial
Protocol: 0.3–4.5 mg · subcutaneous · once weekly · 26 weeks
Population: Adults with overweight or obesity
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Gastrointestinal events were common. Long-term benefit-risk and combination-specific effects remain under study.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Cagrilintide?
A long-acting amylin analog being developed for appetite and weight regulation, including in combination with semaglutide.
Amylin and calcitonin receptor agonist
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Long-term trial schedules; no validated off-cycle
Which diluent and storage period should this material use?
Primary formulation patents investigate buffer, pH, preservative and excipient effects on cagrilintide stability and aggregation. These are formulation-development experiments, not a generic powder-vial label.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeLancet, 2021: Dose-ranging obesity trial
- Formulation-development patent — not a clinical protocolNovo Nordisk formulation patent WO2024256632A1
- Formulation-development patent — not a clinical protocolNovo Nordisk dual-chamber formulation patent
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.